Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Curr Opin Oncol. 2021 May 1;33(3):212-220. doi: 10.1097/CCO.0000000000000721.
As molecular profiling of renal cell carcinoma (RCC) continues to elucidate novel targets for nonclear cell histologies, understanding the landscape of these targets is of utmost importance. In this review, we highlight the genomic landscape of nonclear cell RCC and its implications for current and future systemic therapies.
Several genomic studies have described the mutational burden among nonclear cell histologies. These studies have highlighted the importance of MET in papillary RCC and led to several clinical trials evaluating the efficacy of MET inhibitors for papillary RCC. The success of immune checkpoint inhibitors, such as ipilimumab and nivolumab, in clear cell RCC has led to ongoing trials evaluating these novel therapeutics in nonclear cell RCC.
Genomic profiling has allowed for the evaluation of novel targets for nonclear cell RCC. This evolving therapeutic landscape is being explored in promising, ongoing trials that have the potential for changing how nonclear cell RCC is managed.
随着肾细胞癌 (RCC) 的分子谱分析不断揭示出非透明细胞组织的新靶标，了解这些靶标的情况至关重要。在这篇综述中，我们强调了非透明细胞 RCC 的基因组景观及其对当前和未来系统治疗的影响。
几项基因组研究描述了非透明细胞组织中的突变负担。这些研究强调了 MET 在乳头状 RCC 中的重要性，并导致了几项临床试验评估 MET 抑制剂在乳头状 RCC 中的疗效。免疫检查点抑制剂（如 ipilimumab 和 nivolumab）在透明细胞 RCC 中的成功应用，促使人们正在进行评估这些新型治疗药物在非透明细胞 RCC 中的疗效的临床试验。
基因组谱分析为非透明细胞 RCC 的新靶标评估提供了可能。这一不断发展的治疗领域正在探索中，有希望的正在进行的临床试验有可能改变非透明细胞 RCC 的治疗管理方式。
